Head-to-head evidence
ABBV-RGX-314 vs Brolucizumab-Dbll
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
ABBV-RGX-314
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
Brolucizumab-Dbll
Marketed by Novartis
NCT05672979 · Phase 3 · status unknown
This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-RGX-314's landscape · Brolucizumab-Dbll's landscape